Lymphocyte-To-C-Reactive Protein Ratio Is A Potential New Prognostic Biomarker for Patients with Lung Cancer

Abstract

Aim: To compare and evaluate the prognostic value of various pretreatment combinations of inflammatory factors in patients with lung cancer (LC). Materials & methods: This study enrolled 1005 patients with LC and categorized into a discovery cohort and a validation cohort. Results: A combination of Lymphocyte-to-C-reactive protein levels (LCR) demonstrated the highest correlation with poor first-line progression-free survival (PFS) and overall survival (OS) (p < 0.05), but not disease-free survival (p > 0.05) compared with other parameters in LC patients. Decreased preoperative LCR was an independent prognostic factor for first-line PFS and OS (p < 0.05), but not disease-free survival (p > 0.05) in patients. Conclusion: Pretreatment LCR is a promising biomarker for first-line PFS and OS in patients with LC.

Keywords:

• biomarker
• C-reactive protein
• lung cancer
• lymphocyte
• prognostic

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/bmm-2019-0452

Acknowledgements

The authors thank all the participants in this study. This paper is dedicated to all cancer patients and wish you best regards.

Financial & competing interests disclosure

This study was supported by a grant from the National Natural Science Foundation of China (grant number: 81602468). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance using Enago was utilized in the production of this manuscript, funded by National Natural Science Foundation of China (grant number: 81602468).

Ethical conduct of research

This study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center. Our work followed the most up to date version of the Declaration of Helsinki (2013). Written informed consent was obtained from all the patients.

Data sharing statement

The authors state that our manuscript are neither the original results of a clinical trial nor the secondary analysis of clinical trial data.

Additional information

Funding

This study was supported by a grant from the National Natural Science Foundation of China (grant number: 81602468). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.